Would it be correct to say that BTX 1503 would be class leading...

Would it be correct to say that BTX 1503 would be class leading if it was judged off of the Australian trial results?
Deff something you could argue when you look at the results + the almost no negative side effects (all of the current drugs have really nasty effects).

I think its also important to remember the environment we were in at that time, there were only two companies in America that we could have gone to as 'approved suppliers' and needed DEA approval as the synthetic is "cannabis-derived", it was known in the cannabis clinical trial community how lacking the quality was, and this would have been the first time that they had done a cannabis synthetic and permatex combo. However, when you are first that's just the issues that you have to jump over when it comes to manufacturing. Botanix got a letter from the DEA a few months later so they don't have to get sign-off each time. (not like we could have shipped it from Australia to America either so that they were the same batch - the joy of it being class a drug)


Does anyone know what phase 2 cost or what phase 3 will cost?
well given its derma - some of the cheapest clinical trials you can do. (it's not brain surgery on a rare condition). But it will also be up to the FDA to decide how large these trials need to be. e.g. are we talking 2x 300 cohort studies for phase 3? or 5x - we assume on the smaller end due to the current little to no negative effects (low risk).